Economic evaluation of voriconazole for the treatment of candidemia in Canadian adults. - Wikidata - wikimedia - TriplyDB

Economic evaluation of voriconazole for the treatment of candidemia in Canadian adults.

Economic evaluation of voriconazole for the treatment of candidemia in Canadian adults.

http://www.wikidata.org/entity/Q37021364

about

Canadian clinical practice guidelines for invasive candidiasis in adults.Cost-effectiveness analysis of anidulafungin versus fluconazole for the treatment of invasive candidiasis.

P2860

Q34237335-ACFE3933-D30F-4259-AEB9-78C32A924679 Q44612152-CC933E79-3815-459D-84E3-0A9C93ACECBE

P2860

Economic evaluation of voriconazole for the treatment of candidemia in Canadian adults.

http://www.wikidata.org/entity/Q37021364

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on May 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Economic evaluation of voriconazole for the treatment of candidemia in Canadian adults.

@en

Economic evaluation of voriconazole for the treatment of candidemia in Canadian adults.

@nl

type

label

Economic evaluation of voriconazole for the treatment of candidemia in Canadian adults.

@en

Economic evaluation of voriconazole for the treatment of candidemia in Canadian adults.

@nl

prefLabel

Economic evaluation of voriconazole for the treatment of candidemia in Canadian adults.

@en

Economic evaluation of voriconazole for the treatment of candidemia in Canadian adults.

@nl

P1433

Q37021364-0152E0ED-D986-4E30-972C-99C55AE71782

P1476

Q37021364-72D4637B-BC58-4FF2-B990-266491865662

P2093

Q37021364-0EB1F2FE-0EE6-45B8-AD2F-F789276E4F84

Q37021364-27934498-CAAD-471B-876E-7CA097432E5B

Q37021364-36093F0F-2068-414E-8ED9-97B0614E354F

Q37021364-46DB729F-B192-4481-B0E2-8793D6C7C105

Q37021364-68B51B73-774A-47FB-AA3D-4B2040E1D748

Q37021364-81E166FE-1B3E-4BBB-8918-61CF21FBDF4C

Q37021364-B3701EEF-669B-4503-A9C6-3DC23ED6CF51

Q37021364-F3DC8CCD-2EEA-40E3-9660-208F7950D64E

P2860

Q37021364-18407312-A97E-44AE-9430-1FC8B36DA61F

Q37021364-33683F15-0903-4BF0-9EB9-6BC7CA603A50

Q37021364-46F8B805-CB1C-48A0-A9C9-E8FD6CBCAAE6

Q37021364-609999CA-C433-4A78-B659-096C39785B33

Q37021364-778EFB9F-DFAD-40CE-855C-D2BE795BD9DB

Q37021364-8B91E651-EA08-4EA7-B25B-262B6E2DA756

Q37021364-94AFB866-C25C-4E4E-B677-77D4ADB770F2

Q37021364-97452C37-757D-49BD-9655-17F118AAFFB4

Q37021364-9856D86F-0698-418E-BBAA-FFD14F6C2FAB

Q37021364-B1D03950-E4ED-4C3D-8E6A-FA2C7675D3DD

P304

Q37021364-DA2668DC-DD0C-4D1C-819F-31220A417E9B

P31

Q37021364-C177ADBE-B06F-4BCF-9F93-8058BCEAB259

P356

Q37021364-AEC7D661-4C77-4DAE-8EE5-8707EC2FDD0D

P407

Q37021364-2B3E0616-5DA5-46E5-B688-45EDF7C900C1

P433

Q37021364-53DEC4E0-D199-4AF3-8129-44790604B2AD

P478

Q37021364-1EF2BF48-4CB3-4A40-8D43-44BB5332A5CF

P577

Q37021364-D278D108-F0BF-4E94-A091-74244903D9F3

P698

Q37021364-90CA007E-71C6-4FD1-B714-62244AD36077

P932

Q37021364-8EE0CC11-8D8D-401F-AE09-23BC4FA3ABB1

P356

P1433

Canadian Journal of Infectious Diseases & Medical Microbiology

P1476

Economic evaluation of voriconazole for the treatment of candidemia in Canadian adults.

@en

P2093

Alissa Scalera

http://www.w3.org/2001/XMLSchema#string

Coleman Rotstein

http://www.w3.org/2001/XMLSchema#string

Craig Roberts

http://www.w3.org/2001/XMLSchema#string

Eric J Bow

http://www.w3.org/2001/XMLSchema#string

Gary Garber

http://www.w3.org/2001/XMLSchema#string

Lael Cragin

http://www.w3.org/2001/XMLSchema#string

Michel Laverdière

http://www.w3.org/2001/XMLSchema#string

Sonja V Sorenson

http://www.w3.org/2001/XMLSchema#string

P2860

Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial

Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study

Excess mortality, hospital stay, and cost due to candidemia: a case-control study using data from population-based candidemia surveillance.

Mortality and costs of acute renal failure associated with amphotericin B therapy.

Empirical anti-Candida therapy among selected patients in the intensive care unit: a cost-effectiveness analysis.

Handling uncertainty in cost-effectiveness models.

The impact of candidemia on length of hospital stay, outcome, and overall cost of illness.

A cost-effectiveness analysis of caspofungin vs. liposomal amphotericin B for treatment of suspected fungal infections in the UK.

Current treatment strategies for disseminated candidiasis.

Of yeasts and hyphae: a hematologist's approach to antifungal therapy.

P304

219-226

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2008/161835

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P577

2008-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19412378

http://www.w3.org/2001/XMLSchema#string

P932

2605868

http://www.w3.org/2001/XMLSchema#string